Abstract
The prevalence of diabetes has reached epidemic proportions in the developed world and is expect to increase to 5.4% by 2025. This has resulted in an unprecedented number of patients experiencing the macro- and micro-vascular complications of diabetes, such as renal, retinal, neurological and cardiac dysfunction. Premature coronary artery disease and cardiac failure are vastly overrepresented in the diabetic population, with significant morbidity and mortality. In fact, the rate of cardiac events in patients with diabetes is equivalent to non-diabetic patients with a previous myocardial infarction. Epidemiological evidence, combined with the results of large scale trials blocking the renin-angiotensin system (RAS) have provided data to support the hypothesis that angiotensin II and its interaction with the metabolic changes associated with diabetes mellitus is responsible for the pathogenesis of many of these complications. This review focuses on the role of the RAS and the development of diabetic cardiac disease.
Keywords: RAS, Angiotensin II, hypertension, ACE inhibitor, congestive cardiac failure, aldosterone, angiotensin receptor blocker, TGF β1
Current Pharmaceutical Design
Title: Angiotensin II and the Cardiac Complications of Diabetes Mellitus
Volume: 13 Issue: 26
Author(s): K. A. Connelly, A. J. Boyle and D. J. Kelly
Affiliation:
Keywords: RAS, Angiotensin II, hypertension, ACE inhibitor, congestive cardiac failure, aldosterone, angiotensin receptor blocker, TGF β1
Abstract: The prevalence of diabetes has reached epidemic proportions in the developed world and is expect to increase to 5.4% by 2025. This has resulted in an unprecedented number of patients experiencing the macro- and micro-vascular complications of diabetes, such as renal, retinal, neurological and cardiac dysfunction. Premature coronary artery disease and cardiac failure are vastly overrepresented in the diabetic population, with significant morbidity and mortality. In fact, the rate of cardiac events in patients with diabetes is equivalent to non-diabetic patients with a previous myocardial infarction. Epidemiological evidence, combined with the results of large scale trials blocking the renin-angiotensin system (RAS) have provided data to support the hypothesis that angiotensin II and its interaction with the metabolic changes associated with diabetes mellitus is responsible for the pathogenesis of many of these complications. This review focuses on the role of the RAS and the development of diabetic cardiac disease.
Export Options
About this article
Cite this article as:
Connelly A. K., Boyle J. A. and Kelly J. D., Angiotensin II and the Cardiac Complications of Diabetes Mellitus, Current Pharmaceutical Design 2007; 13 (26) . https://dx.doi.org/10.2174/138161207781662984
DOI https://dx.doi.org/10.2174/138161207781662984 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy Prevalence of Chronic Diabetic Complications in Newly Diagnosed versus Known Type 2 Diabetic Subjects in a Sample of Alexandria Population, Egypt
Current Diabetes Reviews Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome
Mini-Reviews in Medicinal Chemistry Non-transfusion Dependent Thalassemias: A Developing Country Perspective
Current Pediatric Reviews Outcome of Heart Failure with Preserved Ejection Fraction: A Multicentre Spanish Registry
Current Cardiology Reviews Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Inflammatory Mechanisms and Redox Status in Periodontal and Cardiometabolic Diseases: Effects of Adjunctive Nutritional Antioxidants and Statins
Infectious Disorders - Drug Targets Non-Insulin Dependent Diabetes Mellitus: Present Therapies and New Drug Targets&#
Mini-Reviews in Medicinal Chemistry Autoimmune Hepatitis: Pathophysiology, Diagnosis and Pharmacological Therapy
Current Immunology Reviews (Discontinued) Pitavastatin Combined with Ezetimibe Treatment was an Effective Approach to Non-IRA Lesion of ST-segment Elevation Myocardial Infarction Patients with Primary Percutaneous Coronary Intervention
Current Pharmaceutical Biotechnology Effects of Synthetic Peptides on the Inflammatory Response and their Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon
Current Drug Targets Functional Networks in Diabetes-Progression by Comparison of Gene Expression in Three Tissues of Goto-Kakizaki Rats
Current Bioinformatics ATP-Sensitive K+ Channels: Current and Putative Target for the Prevention and Treatment of Cardiovascular Diseases
Vascular Disease Prevention (Discontinued) Preventing Atherosclerosis with Angiotensin-Converting Enzyme Inhibitors: Emphasis on Diabetic Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Status of Stem Cell Based Clinical Trials in the Treatment for Diabetes
Current Diabetes Reviews Beneficial Effects of the Mediterranean Diet on Metabolic Syndrome
Current Pharmaceutical Design New-onset Diabetes Mellitus: Predictive Factors and Impact on the Outcome of Patients Undergoing Liver Transplantation
Current Diabetes Reviews Cardiovascular Disease in the Rheumatic Diseases: How Systemic Inflammation May Contribute to Atherogenesis
Current Rheumatology Reviews Supplementation, Optimal Status, and Analytical Determination of Vitamin D: Where are we Standing in 2012?
Anti-Cancer Agents in Medicinal Chemistry